ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 658

Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels  

Maarten R. Hillen1,2, Sofie L.M. Blokland1,2, Elena Chouri1,2, Aike A. Kruize1, Marzia Rossato1,2, Joel A.G. van Roon1,2 and Timothy R.D.J. Radstake1,2, 1Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 2Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: MicroRNA, Sjogren's syndrome and dendritic cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Sjögren's Syndrome - Poster I: Translational Science

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Plasmacytoid dendritic cells (pDCs) are indicated to be key players in the pathogenesis of primary Sjögren’s syndrome (pSS) and important producers of type-1 interferon (IFN). This is based on their increased presence in pSS salivary glands, potential role in experimental animal models and the presence of an IFN signature in pSS patients, which is associated with disease activity measures. MicroRNAs are key regulators of cellular function and play a pivotal role in cellular function. To study potential dysregulation of pDCs of pSS patients, we investigated the expression of micro-RNAs (miRNA) in these cells in patients with pSS.

Methods:   Two independent cohorts (discovery and validation) were established including a total of 30 pSS patients who were classified according to the 2002 criteria. 15 healthy controls (HC) were included as control group and divided over the two cohorts. CD304-expressing cells were isolated from peripheral blood using MACS and profiling of 758 miRNA was performed using the OpenArray platform. miRNAs found to be differentially expressed in the discovery cohort (p<0.05, with at least a difference between the groups of log2) were subsequently measured in an independent validation cohort using a custom made array. Experimentally supported targets of validated miRNAs were used to perform pathway enrichment in order to assess the functional role of the dysregulated miRNAs.

Results:  Twenty-four miRNAs were significantly downregulated in pSS patients versus HC in the discovery cohort. 15 of these miRNAs were selected to be measured in the validation cohort, of which ten miRNAs were subsequently validated (p<0.05). Pathway enrichment indicated that these miRNAs are mainly involved in regulation of growth factor signalling and cell cycle (FDR corrected, p<0.05). We are currently studying the involvement of these miRNAs in pDC function and their correlation with their experimentally supported targets.  

Conclusion:  Ten miRNAs are expressed at lower levels in pDCs of patients with pSS as compared to healthy controls. Considering the potential of miRNAs in regulation of cell function, these data suggest a significant contribution to pDC function of miRNA dysregulation. Further analysis of the pathways in which these miRNAs are involved will expand our understanding on the role of pDCs in pSS.


Disclosure: M. R. Hillen, None; S. L. M. Blokland, None; E. Chouri, None; A. A. Kruize, None; M. Rossato, None; J. A. G. van Roon, None; T. R. D. J. Radstake, None.

To cite this abstract in AMA style:

Hillen MR, Blokland SLM, Chouri E, Kruize AA, Rossato M, van Roon JAG, Radstake TRDJ. Decreased Expression of Ten Micro-RNAs in Plasmacytoid Dendritic Cells of Patients with Primary SS Indicates Dysregulation on Multiple Levels   [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/decreased-expression-of-ten-micro-rnas-in-plasmacytoid-dendritic-cells-of-patients-with-primary-ss-indicates-dysregulation-on-multiple-levels/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-expression-of-ten-micro-rnas-in-plasmacytoid-dendritic-cells-of-patients-with-primary-ss-indicates-dysregulation-on-multiple-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology